Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0043320200430080788
Archives of Pharmacal Research
2020 Volume.43 No. 8 p.788 ~ p.797
Setosphapyrone C and D accelerate macrophages cholesterol efflux by promoting LXR¥á/ABCA1 pathway
Li Ting

Yin Jiayu
Ji Yubin
Lin Ping
Li Yanjie
Yang Zixun
Hu Shumei
Wang Jin
Zhang Baihui
Koshti Saloni
Wang Junfeng
Ji Chenfeng
Guo Shoudong
Abstract
LXR¥á agonists have attracted significant attention due to their potential biological activities on promoting cholesterol efflux. This study was designed to investigate whether setosphapyrone C and D have potential lipid-lowering capacity and the underlying mechanisms in vitro. Our data showed that setosphapyrone C and D had weak cytotoxicity compared to the liver X receptor ¥á (LXR¥á) agonist T0901317. In RAW 264.7 macrophages, setosphapyrone C and D significantly enhanced [3H]-cholesterol efflux by ~?21.3% and 32.4%, respectively; furthermore, setosphapyrone C and D enhanced the protein levels of ATP-binding cassette transporter (ABC) A1 and LXR¥á by 58% and 69%, and 60% and 70% (8 ¥ìM), respectively; however, they had no effect on the protein levels of ABCG1 and scavenger receptor B type 1; additionally, they had minor effect on the mRNA expression of lipogenic genes. Of note, setosphapyrone C and D significantly enhanced LXR¥á/ABCA1pathway in mice primary macrophages. In BRL cells, setosphapyrone C and D significantly improved the protein levels of ABCA1 and ABCG1; setosphapyrone D significantly enhanced the protein expression of low-density lipoprotein. Collectively, setosphapyrone C and D with weak cytotoxicity exhibited effective lipid-lowering effect via enhancing LXR¥á/ABC pathways. Setosphapyrones possess potential application for the treatment of hyperlipidemic diseases.
KEYWORD
LXR antagonist, Reverse cholesterol transport, Hyperlipidemia, ATP-binding cassette transporter
FullTexts / Linksout information
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI)